IRF7 as an Immune-Related Prognostic Biomarker and Associated with Tumor Microenvironment in Low-Grade Glioma.
glioma
interferon regulatory factor 7
survival analysis
tumor-infiltrating immune cells
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
06
2021
accepted:
22
07
2021
entrez:
20
8
2021
pubmed:
21
8
2021
medline:
21
8
2021
Statut:
epublish
Résumé
Tumor microenvironment (TME) affects the occurrence and progression of low-grade glioma (LGG). The aim of this study is to identify TME-related genes that influence prognosis in LGG patients and to explore their function and role in tumor immunity. The TME components of LGG samples in the Cancer Genome Atlas (TCGA) database were identified by the ESTIMATE method, and differentially expressed genes (DEGs) with significant differences in immune scores and stromal scores were screened out. The core genes of DEGs were screened out by protein-protein interaction (PPI) network. Furthermore, immune-related target genes significantly correlated with prognosis were identified. Survival analysis and correlation analysis showed the correlation between target genes and clinical features and prognosis. The expression differences of target genes were verified by external database Chinese Glioma Genome Atlas (CGGA). CIBERSORT software identified the proportion of tumor-infiltrating immune cells (TICs) that were significantly related to target genes. Gene set enrichment analysis (GSEA) could enrich the main functions related to high and low expression of target genes. A total of 1567 DEGs were screened out from 529 LGG samples in the TCGA database, and 146 immune-related genes affecting prognosis were found. A total of 403 core genes were obtained from PPI network. The target gene interferon regulatory factor 7 (IRF7) was significantly associated with prognosis and clinical features of the tumor. The CGGA database verified the relationship between high and low expression groups of IRF7 and prognosis. GSEA indicated that IRF7 was mainly enriched in immune-related activities, significantly correlated with T cells CD8, macrophages M1, macrophages M2 and monocytes. The IRF7 is involved in immune responses in TME of LGG, which in turn influenced tumor occurrence and progression. IRF7 can act as a potential biomarker for prognosis in patients with LGG and provide a target for tumor immunotherapy.
Identifiants
pubmed: 34413671
doi: 10.2147/IJGM.S324307
pii: 324307
pmc: PMC8371259
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4381-4393Informations de copyright
© 2021 Peng et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Nat Med. 2012 Aug;18(8):1224-31
pubmed: 22820642
Semin Immunol. 2018 Feb;35:19-28
pubmed: 29254756
J Virol. 2000 Feb;74(3):1061-8
pubmed: 10627515
Cold Spring Harb Perspect Med. 2012 Dec 01;2(12):a006676
pubmed: 23209177
J Biol Chem. 2002 May 10;277(19):16592-8
pubmed: 11877397
Curr Opin Immunol. 2013 Apr;25(2):261-7
pubmed: 23579076
Nat Rev Immunol. 2009 Aug;9(8):535-42
pubmed: 19556980
Lancet Oncol. 2011 Jun;12(6):583-93
pubmed: 21474379
Brain. 2012 Apr;135(Pt 4):1055-69
pubmed: 22434214
Life Sci. 2021 Jan 1;264:118709
pubmed: 33152351
Cell Mol Immunol. 2015 Sep;12(5):580-91
pubmed: 26166762
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Cancer Discov. 2015 Sep;5(9):915-9
pubmed: 26272491
Semin Cancer Biol. 2008 Oct;18(5):349-55
pubmed: 18467122
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Mol Immunol. 2013 Oct;55(3-4):283-91
pubmed: 23548837
J Virol. 2003 Sep;77(17):9359-68
pubmed: 12915551
Genes Immun. 2011 Sep;12(6):399-414
pubmed: 21490621
Cancer Lett. 2020 Apr 28;476:1-12
pubmed: 32044356
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Cell Death Dis. 2014 Dec 04;5:e1557
pubmed: 25476905
Int Rev Cell Mol Biol. 2020;350:63-118
pubmed: 32138904
Biochem Pharmacol. 2006 Nov 30;72(11):1469-76
pubmed: 16846591
Curr Opin Neurol. 2016 Dec;29(6):782-788
pubmed: 27676279
Mediators Inflamm. 2016;2016:6058147
pubmed: 26966341
Expert Rev Anticancer Ther. 2015;15(8):943-54
pubmed: 26098949
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931